GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » Shares Outstanding (Diluted Average)

NeuBase Therapeutics (NeuBase Therapeutics) Shares Outstanding (Diluted Average) : 2.76 Mil (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is NeuBase Therapeutics Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. NeuBase Therapeutics's average diluted shares outstanding for the quarter that ended in Sep. 2023 was 2.76 Mil.


NeuBase Therapeutics Shares Outstanding (Diluted Average) Historical Data

The historical data trend for NeuBase Therapeutics's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Shares Outstanding (Diluted Average) Chart

NeuBase Therapeutics Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Shares Outstanding (Diluted Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.14 0.41 0.98 1.37

NeuBase Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.61 1.65 1.68 1.69 2.76

NeuBase Therapeutics Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


NeuBase Therapeutics  (NAS:NBSE) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


NeuBase Therapeutics Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuBase Therapeutics (NeuBase Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
Executives
Symetryx Corp 10 percent owner 2828 BATHURST ST #400, TORONTO A6 M6B3A7
Aleta Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
Barry Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
William Roland Mann officer: COO 700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Todd P. Branning officer: Chief Financial Officer C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Sandra Rojas-caro officer: Chief Medical Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746
Kianoush Motesharei officer: See Remarks 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Gerald J Mcdougall director 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Gines Diego Miralles director 2235 VIA FRESCA, LA JOLLA CA 92037
Franklyn G Prendergast director
Dietrich A Stephan director, 10 percent owner, officer: President and CEO 213 SMITHFIELD ST, PITTSBURGH PA 15222
Lipizzaner Llc 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801